Systemic amyloidoses are potentially lethal ... amyloidosis and intensive chemotherapy in immunoglobulin light chain (AL) amyloidosis. These therapies often elicit substantial morbidity and ...

This important study identifies the "H-state" as a potential conformational marker distinguishing amyloidogenic from non-amyloidogenic light chains, addressing a critical problem in protein misfolding ...

The investigational treatment is currently being evaluated in a 3-part phase 1 trial (ClinicalTrials.gov Identifier: NCT05521022) in adult patients with systemic amyloidosis, as well as a phase 2 open ...

As a result, the company expects AT-02 to bind specifically to amyloid in systemic amyloidosis patients ... Phase 1 trial and a Phase 2 open label extension trial in ATTR and AL amyloidosis patients.

The leading AL Amyloidosis Companies such as Caelum Biosciences, Nexcella, Inc., HaemaLogiX Ltd., Prothena, ZENTALIS ...

Stand Up To Cancer (SU2C) today announced a collaboration with Johnson & Johnson aimed at supporting research testing a combination of two types of targeted therapies, teclistamab and daratumumab, to ...

Different types of systemic amyloidosis are recognized depending ... amyloid A amyloidosis (AA), immunoglobulin light chain amyloidosis (AL) and transthyretin-related amyloidosis (ATTR).

The investigational treatment is currently being evaluated in a 3-part phase 1 trial (ClinicalTrials.gov Identifier: NCT05521022) in adult patients with systemic amyloidosis, as well as a phase 2 ...